Evogene (EVGN)
NASDAQ:EVGN
Want to see EVGN full AI Analyst Report?
Top Page
Evogene
(NASDAQ:EVGN)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.72
▼(-34.73% Downside)
Action:Reiterated
Date:05/20/26
The score is weighed down primarily by weak financial performance (ongoing losses, cash burn, and negative equity) and bearish technicals (below major moving averages with negative MACD). Earnings-call updates add some support from platform and pipeline momentum, but are offset by sharp revenue decline, higher net loss, and funding/runway risk; valuation provides limited help due to a negative P/E and no dividend.
Positive Factors
AI platform partnerships
A second collaboration with Google Cloud strengthens Evogene's proprietary ChemPass AI, accelerating dataset creation and model accuracy. Structural tech partnerships boost platform differentiation, lower discovery cost per candidate and increase the firm's ability to secure future partner-funded programs over the medium term.
Negative Factors
Negative shareholders' equity
Negative stockholders' equity signals cumulative losses and erodes financial resilience. This structural balance-sheet weakness limits capacity to absorb further losses, increases reliance on external financing, and raises the risk of dilutive capital raises that could impair long-term investor returns.
Read all positive and negative factors
Positive Factors
Negative Factors
AI platform partnerships
A second collaboration with Google Cloud strengthens Evogene's proprietary ChemPass AI, accelerating dataset creation and model accuracy. Structural tech partnerships boost platform differentiation, lower discovery cost per candidate and increase the firm's ability to secure future partner-funded programs over the medium term.
Read all positive factors
Evogene (EVGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.47M
Dividend YieldN/A
Average Volume (3M)115.16K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth-53.54%
EPS Growth62.24%
CountryUS
Employees117
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.17
Shares Outstanding12,103,764
10 Day Avg. Volume235,429
30 Day Avg. Volume115,158
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-105.63
Price to Sales (P/S)2.25
P/FCF Ratio-0.64
Enterprise Value/Market Cap-0.60
Enterprise Value/Revenue-1.28
Enterprise Value/Gross Profit-9.57
Enterprise Value/Ebitda0.45
Forecast
1Y Price Target
$2.25Price Target Upside104.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$2.15M
Evogene Business Overview & Revenue Model
Company Description
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Co...
How the Company Makes Money
null...
Evogene Earnings Call Summary
Earnings Call Date:May 20, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 26, 2026
Earnings Call Sentiment Neutral
The call presented strong technology and pipeline progress — notable AI/Google collaborations, a rapidly growing pharma collaboration slate, and demonstrable iterative success in the Ag fungicide program — which are meaningful strategic achievements. However, these operational and R&D advances are contrasted by material near-term financial weakness: an ~87% revenue decline year-over-year, increased net loss driven largely by financing charges, the termination of a Bayer collaboration for biological reasons, and a modest cash balance that implies limited runway without further funding or cash inflows. Overall, business momentum on the technology and pipeline front is positive, but short-term financial and commercial metrics are weak and present risk.Positive Updates
Strategic Technology Partnerships and Platform Advancement
Expanded Campus AI capabilities via continued collaboration with Google (second collaboration announced Feb 2026) to integrate advanced AI agents, enabling automated extraction of insights from scientific literature, creation of proprietary datasets and building more accurate computational models — positioned to materially strengthen Evogene's technological leadership in small-molecule discovery.
Negative Updates
Sharp Revenue Decline
Total revenues for Q1 2026 were approximately $0.3 million versus $2.3 million in Q1 2025 — a decline of about $2.0 million (~87% decrease). Management attributed most of the decline to lower one-time seat sales in 2025 (~$2 million).
Read all updates
Q1-2026 Updates
Positive
Negative
Strategic Technology Partnerships and Platform Advancement
Expanded Campus AI capabilities via continued collaboration with Google (second collaboration announced Feb 2026) to integrate advanced AI agents, enabling automated extraction of insights from scientific literature, creation of proprietary datasets and building more accurate computational models — positioned to materially strengthen Evogene's technological leadership in small-molecule discovery.
Read all positive updates
Company Guidance
Management guided that they expect “meaningful progress” across all three core areas—technology, pharma and ag-chemicals—driven by additional technology collaborations (including the second Google engagement), new and expanding pharma partnerships and continued advancement of internal ag and pharma pipelines. Financially, they reported approximately $13.1 million of consolidated cash as of March 31, 2026 with Q1 cash usage of about $2.8 million, noted recent warrant-induced gross proceeds of roughly $3.4 million (with a related warrants liability of ~$1.7 million) and reminded investors of anticipated subsidiary cash distributions (Lavie $4.25M, Biomica $2.7M) expected in Q2. Quarterly operating metrics included Q1 revenue of ~$0.3M (down from $2.3M), cost of revenues ~$0.1M, R&D ~$1.8M, S&M ~$0.4M, G&A ~$1.2M, operating loss of ~$3.2M and net loss of ~$5.9M (driven by ~$2.7M net financing expense and a ~$3.8M warrant-related financing charge). On product development they highlighted concrete ag screening results (initial 440 candidates → 11 enzymatic hits/2 antifungal; follow-up 164 → 38 inhibiting/5 antifungal; then 27 novel → 25 enzymatic hits/15 biologically active), reiterated the Septoria market opportunity of >$1.2B (70% of EU wheat fungicide use targets this disease) and noted a >$26B addressable opportunity in demyelinating disorders, while cautioning that strategic pharma licensing or equity investments are likely to follow demonstration of near-term value-creating milestones rather than occur within the next few quarters.Evogene Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.85M | 8.51M | 5.64M | 1.68M | 930.00K |
| Gross Profit | 795.00K | 3.39M | 1.40M | -1.77M | -2.07M |
| EBITDA | -12.85M | -15.38M | -23.20M | -26.93M | -27.80M |
| Net Income | -8.48M | -16.48M | -23.88M | -26.64M | -27.79M |
Balance Sheet | |||||
| Total Assets | 20.05M | 39.86M | 51.10M | 56.13M | 76.30M |
| Cash, Cash Equivalents and Short-Term Investments | 12.99M | 15.31M | 31.06M | 35.35M | 53.87M |
| Total Debt | 2.20M | 12.87M | 11.51M | 11.93M | 2.67M |
| Total Liabilities | 5.00M | 25.03M | 22.42M | 21.34M | 12.88M |
| Stockholders Equity | -82.00K | -1.45M | 12.05M | 27.93M | 53.65M |
Cash Flow | |||||
| Free Cash Flow | -13.64M | -20.33M | -22.36M | -24.85M | -25.56M |
| Operating Cash Flow | -13.50M | -19.70M | -21.58M | -23.68M | -24.84M |
| Investing Cash Flow | 17.74M | 9.62M | -4.54M | 13.27M | -20.44M |
| Financing Cash Flow | -6.60M | 4.66M | 18.15M | 9.34M | 30.28M |
Evogene Technical Analysis
Negative
1.10
Price Trends
0.80
Negative
0.89
Negative
1.05
Negative
Market Momentum
-0.02
Positive
43.97
Neutral
14.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVGN, the sentiment is Negative. The current price of 1.1 is above the 20-day moving average (MA) of 0.77, above the 50-day MA of 0.80, and above the 200-day MA of 1.05, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.97 is Neutral, neither overbought nor oversold. The STOCH value of 14.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EVGN.
Evogene Risk Analysis
Evogene disclosed 62 risk factors in its most recent earnings report. Evogene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Evogene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $142.38M | -0.65 | -116.86% | ― | -98.25% | 76.83% | |
43 Neutral | $8.47M | -0.45 | 553.15% | ― | -53.54% | 62.24% | |
43 Neutral | $8.38M | -0.26 | -97.58% | ― | 78.64% | 50.70% | |
42 Neutral | $70.54M | -7.35 | -53.86% | ― | -20.00% | 75.26% | |
40 Underperform | $4.66M | -2.45 | -154.50% | ― | ― | 59.90% | |
39 Underperform | $613.50K | ― | -1302.82% | ― | ― | 99.09% |
* Healthcare Sector Average
EVGN
Evogene
0.72
-0.46
-39.07%
IBIO
Ibio
1.70
0.93
120.78%
KZIA
Kazia Therapeutics
12.97
9.52
275.94%
WINT
Windtree Therapeutics
0.02
-0.77
-97.85%
PHGE
BiomX
0.60
-9.48
-94.09%
BOLT
Bolt Biotherapeutics
4.61
-1.73
-27.29%
Evogene Corporate Events
Evogene Tightens Focus on AI Small-Molecule Platform as Q1 2026 Revenue Falls
May 20, 2026
On May 20, 2026, Evogene reported first-quarter 2026 results, highlighting the post-2025 strategic focus on its ChemPass AI engine and pipeline in pharma and agriculture, alongside the wind-down of non-core subsidiaries. Management is concentratin...
Evogene’s Ag Plenus, Bayer End Herbicide Collaboration as APTH1 Target Falls Short
May 18, 2026
On May 18, 2026, Evogene announced that its subsidiary Ag Plenus and Bayer Ag mutually agreed to terminate their joint herbicide development project after concluding that the APTH1 target protein failed to meet required product criteria. The termi...
Evogene Faces Nasdaq Minimum Bid Price Deficiency, Granted Cure Period to September 2026
Apr 2, 2026
On April 2, 2026, Evogene disclosed it had received a notification from Nasdaq that its ordinary shares failed to meet the exchange’s minimum bid price requirement of $1.00 for 30 consecutive business days. The notice triggers an initial 180...
Evogene Reshapes AI-Driven Molecule Business With 2025 Results and Strategic Overhaul
Mar 5, 2026
On March 5, 2026, Evogene reported its fourth-quarter and full-year 2025 results, highlighting a strategic overhaul that consolidated the business around its ChemPass AI engine for small-molecule discovery in pharma and agriculture and exited non-...
Evogene Details 2025 Strategic Refocus Around ChemPass AI and Core Health, Agriculture Markets
Feb 25, 2026
On February 25, 2026, Evogene released a CEO letter to shareholders outlining a strategic transformation undertaken in 2025 to sharpen its focus and capital allocation. The company consolidated technology development around its ChemPass AI™ ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.